A fundamental property of CAR-T cells that supports their application to cancer therapy is represented by their capacity to promote recognition and killing of target cells in a major histocompatibility complex (MHC)-independent manner, thus bypassing a physiological mechanism required by normal T cells; the bypass of MHC restriction by CAR-T cells is an important property since MHC downregulation represents one of the key mechanisms of immune escape adopted by cancer cells [1]. The gene discussed is HLA-C; the disease is cancer.